ReviewAmerican journal of translational research2023
Meta-analysis of the clinical effect of Kanglaite injection-assisted gemcitabine plus cisplatin regimen on non-small cell lung cancer.
Review in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Retrospective analysis of the curative effect of Kanglaite injection on pancreatic cancer.Journal of medical biochemistry · 2026Article
- Predictive value analysis of CEA, CA125 and CYFRA21-1 levels in evaluating the efficacy of tislelizumab combined with gemcitabine-cisplatin chemotherapy in patients with advanced non-small cell lung cancer.Oncology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the clinical effect of Kanglaite (KLT) injection-assisted gemcitabine plus cisplatin (GP) regimen on non-small cell lung cancer (NSCLC).
methodsThe CNKI, WanFang, VIP, Chinese Biomedical Database, PubMed, Embase and Cochrane Library databases were searched to collect the randomized controlled trials (RCTs), which evaluated the clinical effect of KLT combined with GP chemotherapy on NSCLC, published as of February 15, 2023. These articles were screened, extracted and evaluated. Revman 5.3 and STATA 17 were used for analysis, where the odds ratio (OR) was used as the statistic for the binary variables, and the mean difference (MD) was used as the statistic for the continuous variables.
resultsAfter selection, this meta-analysis included 27 RCTs and 2,579 patients. Comparing with GP chemotherapy, KLT combined with GP regimen enhanced the total response rate (
conclusionsCurrent evidence shows that the combination regimen of KLT with GP has shown promising results in increasing the response rate, improving the KPS score, enhancing the immune level, and reducing the incidence of adverse reactions in NSCLC patients. However, this conclusion needs to be further verified due to limitations such as the limited number of articles included in this paper and the variability in research methodology and quality among the included studies.
Indexed as
Identifiers
37303638PMC10250993W4380291939What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.